Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B6ZM0X53 ORD 5P
  Price Change % Change Share Price Shares Traded Last Trade
  0.00 0.0% 16.50 0.00 01:00:00
Bid Price Offer Price High Price Low Price Open Price
16.25 16.75
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 11.03 -18.86 -21.30 14
Last Trade Time Trade Type Trade Size Trade Price Currency
- O 0 16.50 GBX

Hvivo (HVO) Latest News

More Hvivo News
Hvivo Investors    Hvivo Takeover Rumours

Hvivo (HVO) Discussions and Chat

Hvivo Forums and Chat

Date Time Title Posts
20/1/202007:09hVIVO plc2,748

Add a New Thread

Hvivo (HVO) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Hvivo trades in real-time

Hvivo (HVO) Top Chat Posts

DateSubject
20/10/2020
09:20
Hvivo Daily Update: Hvivo Plc is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker HVO. The last closing price for Hvivo was 16.50p.
Hvivo Plc has a 4 week average price of 0p and a 12 week average price of 0p.
The 1 year high share price is 17.75p while the 1 year low share price is currently 10.63p.
There are currently 83,664,276 shares in issue and the average daily traded volume is 0 shares. The market capitalisation of Hvivo Plc is £13,804,605.54.
16/1/2020
09:33
qs99: Wonder how far this will go before last day of dealings tomorrow isn't it? Market appears to be marking up Orphan and therefore value inherent in HVO....20p soon? DYOR
15/1/2020
14:40
qs99: will take a look through docs, but anyone know off top of head when shares will stop trading as HVO?
13/1/2020
16:53
discojames: HVO rise is meaningless now, as we are committed to moving to ORPH at 2.47x
31/12/2019
13:38
muchodinero: I wouldn't bank on it with that Muppet Trev in charge of the business. He's been a disaster at HVO!!!!!!!!!!
16/12/2019
11:05
sunningdale1: Following on from my previous Open Orphans (ORPH) post, Cathal Friel has delivered as promised with the all share merger with hVIVO (HVO). Seeing as HVO was trading at 30p at the start of the year, 2.47 ORPH shares for for each HVO share at 15.6p is great value. This follows partnerships with biopharma giant Ipsen Group and Venn’s deal with Carna Bioscience, and will leverage up and commercialise HVO’s sb through the Open Orphan health data platform. At 5.6p this still values ORPH at just £14m - combine in HVO at £11m plus the preferred partnership agreements and ORPH is set for a big 2020
10/12/2019
13:51
muchodinero: Flu v and Zika vaccines within Imutex are to be spun off and HVOs 49%% holding is to remain with existing HVO shareholders according to the investor presentation given by the COO of Orphan.
09/12/2019
19:28
muchodinero: So according to the interview with the COO of Open Orphan, the company is going to raise additional funding in th new year in the "merged company", at a significant premium to the new company's valuation to the benefit of existing shareholders, also existing HVO shareholders will be sole beneficiaries of the 49% stake in Seek Group if Flu-v / Zika vaccines get monitised in the spun out Seek Group assets. Looking much better than I first thought. Maybe Trevor and the BOD won't be shafting the shareholders??? [...]
25/10/2019
16:03
sunningdale1: Nothing happening IMO unfortunately. For those interested in alternative Pharma stocks (if you're not, no problem - this is a shameless plug) Open Orphan AIM:ORPH is one I’d recommend keeping an eye on - Share price has performed well over the last 6 months and it's no surprise - CEO Cathal Friel predicts 40% growth a year on podcast below with 2 million of his own money invested. hxxps://audioboom.com/posts/7361662-open-orphan-orph-ceo-cathal-friel-tells-alan-green-why-he-expects-40-percent-growth-year-on-year Their health databank a standout for me and is progressing well. ORPH recently signed an agreement with Empiric Logic, a leading managed software service company. The Collaboration is the final stage in the completion of Open Orphan’s Genomic Health Data platform and will speed up its launch. The companies CCO Maurice Treacy is holding a live webinar on Wednesday 30th October 2019 at 19:00 (UK time) for those interested: hxxps://vtm.clickmeeting.com/orph
24/11/2018
01:06
bernymadoff: This bears all the hallmarks of a shorting attack. The same thing happened last March too and the company was forced to issue a statement saying it saw no reason for the share price drop. People are surmising that LP selling is causing the weakness but there is no evidence of that and also the drop is simply too precipitous for that to be the reason. When the company declared on Oct 1st that LP had fallen below 5% on Sept 26th the share price was still 61.5p and the announcement had little immediate impact on the share price which continued ranging between 60-65p. LP's selling 2.6% of their holding had not had any effect on the share price And here's the real proof LP are not selling. According to HVO website, as of 10th October Lansdowne Partners Limited held 3,827,771 shares or 4.8%. What is interesting is that the drop started a few days later on Oct 9th just one day after the company announced £21m worth of new contracts. Naturally you would expect such positive news to spike or shore up the share price. Strangely however, after a mini spike on the Oct 8 rns, the share price started nosediving. Those who say that it is because LP are selling (as I also initially assumed) are mistaken. The volume of sells should have triggered a TR1 at 4% but it hasn't so my view is that LP haven't sold down beyond this level. What has been evident however is the chunky sells that have been dropped regularly into the market and which have had the effect of tanking the share price. For a short to be effective requires the shorting entity to begin his trade at the top such as after the mini spike on the £21m contracts announced on Oct 8th. The shorters knew that with the company having started the process of selling the Flu-v vaccine to a pharmaceutical major there would likely be no significant news or liquidity event for some time. They also knew that with Woodford having reached the legal ceiling there were no major buyers in the market. Having no counter party that is buying stock has given the shorters a free run. It is no coincidence that the price crash has come AFTER Woodford went above 29% and reached his upper limit. The shorters knew then that with no other major buyers in the market the tiny free float here would make the share price vulnerable to an attack. So that's exactly what they've done. Look at the price action on the chart after the NiH partial PIIb trial results came out last March - the descent is virtually identical. At that time the company even had to issue an rns stating it saw no reason for the decline. The truth of the matter is that the spivs are taking us for all for a ride. I don't know whether it's a broker or the MMs but someone somewhere is making a lot of money bringing the share price down to these levels. With all that being said I think we are near the bottom now simply because the lower we go the more risky it becomes for the shorters. All it takes is a flurry of interest generated by significant news and the share price will be back up in a flash. If the company was to drop an rns tomorrow stating that they are in advanced talks with Sanofi or GSK the demand for shares would be so great that the shorters would struggle to close their positions and the thin free float here would greatly exaggerate the rise. The best example I can remember is Kibo Mining (Kibo) which was the subject of a shorting attack a few years ago. To counter the shorters the company released a series of great RNS' which had them scrambling to cover. Shares in Kibo jumped within days from 1.5p to a high of 14p. I imagine the problem with HVO is that at least one of the MMs is in cahoots with the shorters so they will protect against any such spike catching them out here. It really stinks but until the authorities ban naked shorting this kind of share price manipulation will continue to rob investors of their hard earned money and companies from failing to realise true value on the exchanges.
30/8/2018
08:53
discojames: I disagree, Berny. Any test, with any sample size has the possibility to be flawed. Getting parallel results from an independent body is actually important to verify them and the next step up in the share price. Every party involved (us included) will be very happy to hear that a third party has backed up the incredible results so far, and I can see it having a large affect on the share price. Any major in talks with HVO over Flu-V will be waiting on this verification, why would they sign a deal now when they are so close to reading the NIH findings, unless such a deal included a get-out clauses if NIH results don't back up those of HVO's. It will then just be a question of when rather than if a deal will be signed to move Flu-V to the next stage. I would prefer a takeover or a sale of the rights over a joint venture (I think HVO are targetting the latter), but any of these options work for us obviously, in terms of the share price
Hvivo share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
HVO
Hvivo
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201020 12:39:55